Medical treatment for pulmonary fibrosis: current trends, concepts, and prospects

被引：59

作者：

Brown, KK

Raghu, G

机构：

[1] Natl Jewish Ctr Immunol & Resp Med, Interstitial Lung Dis Program, Denver, CO 80206 USA

[2] Univ Colorado, Hlth Sci Ctr, Div Pulm Sci & Crit Care Med, Denver, CO 80202 USA

[3] Univ Washington, Med Ctr, Seattle, WA 98195 USA

来源：

CLINICS IN CHEST MEDICINE | 2004年 / 25卷 / 04期

关键词：

D O I：

10.1016/j.ccm.2004.08.003

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

A diagnosis of idiopathic pulmonary fibrosis (IPF) carries a poor prognosis, with our currently available therapies offering little clinical benefit. Unfortunately, recent major advances in our understanding of the clinical and biologic features of this disease have not been matched by similar advances in treatment. This is likely because of the complex cascade of biologic and pathobiologic events that occurs in IPF. The necessary, and desperately needed, next generation of therapies, focused on specific molecular targets thought to play pivotal roles in the development and progression of fibrosis, are under active investigation.

引用

页码：759 / +

页数：15

共 131 条

[1]

Enhanced insulin-like growth factor finding protein-related protein 2 (connective tissue growth factor) expression in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis [J].